Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 7, 2011, Pages 1114-1122

  Yoon, Jin Young ^a   Cheon, Jae Hee ^a   Park, Jae Jun ^a   Hong, Sung Pil ^a   Kim, Tae Il ^a   Kim, Won Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Clinical outcome; Corticosteroid; Mayo score; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; HYDROCORTISONE; MESALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCTOCOLECTOMY; REMISSION; SYSTEMIC THERAPY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 79958826408     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06688.x     Document Type: Article

References (38)

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963; 4: 299-308.
2. Jakobovits SL, Travis SP. Management of acute severe colitis. Br. Med. Bull. 2006; 75: 131-44.
3. Truelove SC, Witts U. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br. Med. J. 1955; 2: 1041-8.
4. Hyde GM, Jewell DP. The management of severe ulcerative colitis. Aliment. Pharmacol. Ther. 1997; 11: 419-24.
5. Kjeldsen J. Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment. Scand. J. Gastroenterol. 1993; 28: 821-6.
6. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br. Med. J. 1962; 2: 441-3.
7. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report of a controlled therapeutic trial. Br. Med. J. 1974; 4: 627-30.
8. Gupta S, Keshavarzian A, Hodgson HJ. Cyclosporin in ulcerative colitis. Lancet 1984; 2: 1277-8.
9. Fellerman K, Tanko Z, Herrlinger KR etal. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm. Bowel Dis. 2002; 8: 317-24.
10. Järnerot G, Hertevig E, Friis-Liby I etal. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
11. Kohn A, Daperno M, Armuzzi A etal. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment. Pharmacol. Ther. 2007; 26: 747-56.
12. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 2004; 99: 1371-85.
13. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroids therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
14. Yang SK, Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflamm. Bowel Dis. 2001; 7: 260-70.
15. Park SH, Kim YM, Yang SK etal. Clinical features and natural history of ulcerative colitis in Korea. Inflamm. Bowel Dis. 2007; 13: 278-83.
16. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008; 28: 674-88.
17. D'Haens G, Sandborn WJ, Feagan BG etal. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987; 317: 1625-9.
19. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm. Bowel Dis. 2008; 14: 1660-6.
20. Stange EF, Travis SPL, Vermeire S etal. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J. Crohns Colitis 2008; 2: 1-23.
21. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
22. Jones HW, Grogono J, Hoare AM. Acute colitis in a district general hospital. Br. Med. J. 1987; 294: 683-4.
23. Lindgren SC, Flood LM, Kilander AF, Löfberg R, Persson TB, Sjödahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 1998; 10: 831-5.
24. Travis SP, Farrant JM, Ricketts C etal. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
25. Daperno M, Sostegni R, Scaglione N etal. Outcome of a conservative approach in severe ulcerative colitis. Dig. Liver Dis. 2004; 36: 21-8.
26. Hefti MM, Chessin DB, Harpaz NH, Steinhagen RM, Ullman TA. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis. Colon Rectum 2009; 52: 193-7.
27. Meyers S, Sachar DB, Goldberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 1983; 85: 351-7.
28. Daperno M, Sostegni R, Rocca R etal. Review article: medical treatment of severe ulcerative colitis. Aliment. Pharmacol. Ther. 2002; 16: 7-12.
29. Oshitani N, Matsumoto T, Jinno Y etal. Prediction of short-term outcome for patients with active ulcerative colitis. Dig. Dis. Sci. 2000; 45: 982-6.
30. Mantzaris GJ, Petraki K, Archavlis E etal. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand. J. Gastroenterol. 2001; 36: 971-4.
31. Seo M, Okada M, Yao T, Matake H, Maeda K. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J. Gastroenterol. 2002; 37: 29-34.
32. Meyers S, Lerer PK, Feuer EJ, Johnson JW, Janowitz HD. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J. Clin. Gastroenterol. 1987; 9: 50-4.
33. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol. 2007; 5: 103-10.
34. Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzén H, Tysk C, Järnerot G. Long-term colectomy rate after intensive intravenous corticosteroids therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am. J. Gastroenterol. 2007; 102: 2513-19.
35. Chakravarty BJ. Predictors and the rate of medical treatment failure in ulcerative colitis. Am. J. Gastroenterol. 1993; 88: 852-5.
36. Henriksen M, Jahnsen J, Lygren I etal. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study(the IBSEN Study). Scand. J. Gastroenterol. 2006; 41: 1037-43.
37. Barahona-Garrido J, Camacho-Escobedo J, García-Martínez CI, Tocay H, Cabiedes J, Yamamoto-Furusho JK. Antinuclear antibodies: a marker associated with steroid dependence in patients with ulcerative colitis. Inflamm. Bowel Dis. 2009; 15: 1039-43.
38. Etchevers MJ, Aceituno M, García-Bosch O etal. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm. Bowel Dis. 2009; 15: 1320-5.